WBB Securities Named Co-Manager on Omeros Corporation Underwriting

PDF: 3.19.2014 Omeros Equity Financing

Omeros closes $40.25 million in underwritten public offering

For Immediate Release

March 19, 2014

SAN DIEGO, CAWBB Securities acted as co-manager to a transaction for Omeros Corporation in an underwritten public offering which closed today. Omeros Corporation raised $40.25 million through the transaction. The transaction was related to the sale of of its common stock for gross proceeds of approximately $40.25 million. The closing included the sale of 456,521 shares of common stock sold pursuant to the overallotment option granted by Omeros to the underwriters, which the underwriters exercised in full.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the potential commercialization of Omidria (OMS302), as well as for research and development expenses, such as funding further clinical trials for Omeros’ OMS824 and OMS721 programs. The net offering proceeds may also be used to advance one or more of Omeros’ preclinical programs into clinical trials, to fund preclinical activities, or for capital expenditures, working capital and to otherwise advance Omeros’ product candidates toward commercialization.

About WBB Securities

The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche.  Our investment bank has participated in over 120 transactions leading to $2 billion placed.  Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain.   Our firm has been singled out for its equity research and analytics year after year from our peers for accuracy and performance by the financial industry’s most highly regarded rankings organizations.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system.